

Community Pharmacy Resources to Mitigate the Effects of Wisconsin's Opioid Crisis



Exploring the role of community pharmacistprovided injectable naltrexone (Vivitrol[®]) for treatment court participants.

The increased rates of opioid-related deaths and emergency room visits¹ in Wisconsin underscores the fact that the state's opioid crisis continues to be a major public health issue. The preferred evidence-based treatment for persons with an opioid use disorder (OUD) combines the use of FDA-approved medications for OUD (MOUD) with counseling and behavioral therapies. However, access to MOUD has not kept up with increased demand.

As of 8/31/2021, in WI there have been 835 opioid-related deaths in the year.¹

In Wisconsin, pharmacists are able to provide long-acting injectable naltrexone, an approved and effective MOUD treatment. Pharmacists, who are more geographically accessible, have a unique perspective on what to expect pharmacologically with an OUD medication, and they can proactively follow up with participants once a medication is provided.

Since 2018, the Ford Research Group at the University of Wisconsin-Madison School of Pharmacy, lead by Dr. Jay Ford, has been been researching community pharmacist-provided injectable naltrexone services. Part of our goal is to understand how community pharmacists can potentially benefit treatment court programs. In 2021, we surveyed and conducted a focus group with treatment court coordinators in Wisconsin. What was evident in our findings was that there was widespread lack of awareness about community pharmacistprovided injectable naltrexone. While many barriers were discussed, coordinators could see the the benefit of this collaboration.

"I think getting pharmacists, especially in rural communities, involved in [MOUD] would be extremely helpful."

~ Treatment Court Coordinator

To further inform treatment court coordinators of this service, we held a joint webinar with the Wisconsin Association of Treatment Court Professionals membership and community pharmacists offering injectable naltrexone. A link to the video of the webinar is available via the QR code to the left.

We hope to further explore this potential collaboration with future research funding.

Questions?

fordresearchgroup@pharmacy.wisc.edu

Benefits to Treatment Court Participants

- Increases access to naltrexone injections and related services
- Flexible scheduling (including evenings and weekends)
- Increases convenience to access services outside of clinic visits
- Capitalizes on existing trusted relationship with pharmacist
- Reduces stigma (pharmacy preserves anonymity)
- Minimizes participant travel
- Makes it easier for participants to stay compliant
- Creates clearer participant expectations
- Creates critical access point for people leaving the criminal justice system
- Assists participants with insurance issues

To see the full list of our injectable naltrexone related resources, including a link to the WATCP video, please scan the QR code below.

